Exosomal miR-455-3p from BMMSCs prevents cardiac ischemia-reperfusion injury

Wang, Yue; Shen, Yusi

doi:10.1177/09603271221102508

Cited by 17 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-146-5p was demonstrated to inhibit pro-inflammatory pathways in sepsis [ 58 ] and accelerate diabetic wound healing [ 59 ]. MiR-455-3p was revealed to attenuate LPS-induced injury in bronchial epithelial cells [ 60 ] and prevent cardiac ischemia-reperfusion injury [ 61 ]. MiR-133a was also reported to have a protective effect on sepsis-induced kidney injury [ 62 ].…”

Section: Discussionmentioning

confidence: 99%

Human umbilical cord mesenchymal stromal cell small extracellular vesicle transfer of microRNA-223-3p to lung epithelial cells attenuates inflammation in acute lung injury in mice

Chen,

Ma,

Luo

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Background Acute lung injury (ALI), manifested as strong pulmonary inflammation and alveolar epithelial damage, is a life-threatening disease with high morbidity and mortality. Small extracellular vesicles (sEVs), secreted by multiple types of cells, are critical cellular communication mediators and can inhibit inflammation by transferring bioactive molecules, such as microRNAs (miRNAs). Thus, we hypothesized that sEVs derived from mesenchymal stromal cells (MSC sEVs) could transfer miRNAs to attenuate inflammation of lung epithelial cells during ALI. Methods C57BL/6 male mice were intratracheally administered LPS (10 mg/kg). Six hours later, the mice were randomly administered with MSC sEVs (40 µg per mouse in 150 µl of saline), which were collected by ultracentrifugation. Control group received saline administration. After 48 h, the mice were sacrificed to evaluate pulmonary microvascular permeability and inflammatory responses. In vitro, A549 cells and primary human small airway epithelial cells (SAECs) were stimulated with LPS with or without MSC sEVs treatment. Results In vitro, MSC sEVs could also inhibit the inflammation induced by LPS in A549 cells and SAECs (reducing TNF-α, IL-1β, IL-6 and MCP-1). Moreover, MSC sEV treatment improved the survival rate, alleviated pulmonary microvascular permeability, and inhibited proinflammatory responses (reducing TNF-α, IL-1β, IL-6 and JE-1) in ALI mice. Notably, miR-223-3p was found to be served as a critical mediator in MSC sEV-induced regulatory effects through inhibition of poly (adenosine diphosphate-ribose) polymerase-1 (PARP-1) in lung epithelial cells. Conclusions Overall, these findings suggest that MSC sEVs may offer a novel promising strategy for ALI.

show abstract

Section: Discussionmentioning

confidence: 99%

Human umbilical cord mesenchymal stromal cell small extracellular vesicle transfer of microRNA-223-3p to lung epithelial cells attenuates inflammation in acute lung injury in mice

Chen,

Ma,

Luo

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…However, miR-369-3p, miR-644-5p, and miR-125b-5p in MSCs-Exos exert antiapoptotic effects by inhibiting the activation of p53 [ 32 , 55 – 57 ]. And interestingly, miR-455-3p and miR-19a exhibit antiapoptotic effects by inhibiting JNK and subsequent activation of p53 and caspase-3 [ 58 , 59 ]. Additionally, MSCs significantly alleviate cisplatin-induced toxicity and improve islet viability by inhibiting p38/MAPK pathway [ 46 , 60 – 62 ].…”

Section: Mscs Protect Cells From Apoptosismentioning

confidence: 99%

The dual role of mesenchymal stem cells in apoptosis regulation

Chen,

Xia,

Yao

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are widely distributed pluripotent stem cells with powerful immunomodulatory capacity. MSCs transplantation therapy (MSCT) is widely used in the fields of tissue regeneration and repair, and treatment of inflammatory diseases. Apoptosis is an important way for tissues to maintain cell renewal, but it also plays an important role in various diseases. And many studies have shown that MSCs improves the diseases by regulating cell apoptosis. The regulation of MSCs on apoptosis is double-sided. On the one hand, MSCs significantly inhibit the apoptosis of diseased cells. On the other hand, MSCs also promote the apoptosis of tumor cells and excessive immune cells. Furthermore, MSCs regulate apoptosis through multiple molecules and pathways, including three classical apoptotic signaling pathways and other pathways. In this review, we summarize the current evidence on the regulation of apoptosis by MSCs.

show abstract

“…Second, genetically modified sEVs have shown good potential for IHD treatment. For example, using miR-455-3p, miR-30e, or miR-29c-transfected sEVs could protect myocardial infarction in rodent model ( Li et al, 2020 ; Pu et al, 2021 ; Botello-Flores et al, 2022 ; Wang and Shen, 2022 ), as well as cardioprotective gene-transfected EVs, such as overexpress MIF ( Liu et al, 2020 ), or FNDC5 ( Deng et al, 2020 ), showed better therapeutic efficiency than unmodified EVs. Finally, EVs derived from some drug-pretreated MSCs can promote therapeutic effects; for example, atorvastatin-pretreated BMMSC-derived EVs enhanced therapeutic efficacy for the treatment of acute myocardial infarction by elevating lncRNA-H19 ( Huang et al, 2020 ).…”

Section: Current Progress In Improving Bmmsc-sev Efficiencymentioning

confidence: 99%

Bone marrow mesenchymal stromal cell-derived small extracellular vesicles: A novel therapeutic agent in ischemic heart diseases

Chang

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Myocardial injury is a major pathological factor that causes death in patients with heart diseases. In recent years, mesenchymal stromal cells (MSCs) have been generally used in treating many diseases in animal models and clinical trials. mesenchymal stromal cells have the ability to differentiate into osteocytes, adipocytes and chondrocytes. Thus, these cells are considered suitable for cardiac injury repair. However, mechanistic studies have shown that the secretomes of mesenchymal stromal cells, mainly small extracellular vesicles (sEVs), have better therapeutic effects than mesenchymal stromal cells themselves. In addition, small extracellular vesicles have easier quality control characteristics and better safety profiles. Therefore, mesenchymal stromal cell-small extracellular vesicles are emerging as novel therapeutic agents for damaged myocardial treatment. To date, many clinical trials and preclinical experimental results have demonstrated the beneficial effects of bone marrow-derived mesenchymal stromal cells (BMMSCs) and bone marrow-derived mesenchymal stromal cells-small extracellular vesicles on ischemic heart disease. However, the validation of therapeutic efficacy and the use of tissue engineering methods require an exacting scientific rigor and robustness. This review summarizes the current knowledge of bone marrow-derived mesenchymal stromal cells- or bone marrow-derived mesenchymal stromal cells-small extracellular vesicle-based therapy for cardiac injury and discusses critical scientific issues in the development of these therapeutic strategies.

show abstract

Exosomal miR-455-3p from BMMSCs prevents cardiac ischemia-reperfusion injury

Cited by 17 publications

References 46 publications

Human umbilical cord mesenchymal stromal cell small extracellular vesicle transfer of microRNA-223-3p to lung epithelial cells attenuates inflammation in acute lung injury in mice

Human umbilical cord mesenchymal stromal cell small extracellular vesicle transfer of microRNA-223-3p to lung epithelial cells attenuates inflammation in acute lung injury in mice

The dual role of mesenchymal stem cells in apoptosis regulation

Bone marrow mesenchymal stromal cell-derived small extracellular vesicles: A novel therapeutic agent in ischemic heart diseases

Contact Info

Product

Resources

About